Literature DB >> 16955385

Extent of lymph node retrieval and pancreatic cancer survival: information from a large US population database.

Roderich E Schwarz1, David D Smith.   

Abstract

BACKGROUND: Operative therapy of pancreatic cancer is associated with poor survival because of high recurrence rates after pancreatectomy. The effect of lymph node (LN) dissection on survival continues to be debated.
METHODS: A pancreatic cancer data set was created through structured queries to the Surveillance, Epidemiology, and End Results 1973 to 2000 database. Stage information was created according to 6th edition American Joint Committee on Cancer tumor-node-metastasis criteria, and the effect of LN number on survival was analyzed.
RESULTS: Out of a cohort of 20,631 patients with carcinomas of the exocrine pancreas, surgical details were available for 2,787 patients. Procedures included pancreatoduodenectomies (n = 1848; 66%), radical regional pancreatectomies (n = 516; 19%), other partial resections (n = 316; 11%), and total pancreatectomies (n = 107; 4%). For 1666 of these patients with complete clinicopathologic information, the median age was 66 years (range, 22-96 years), with an equal sex ratio. The median number of total LNs examined was 7 (range, 1-52), of positive LNs was 1 (range, 0-34), and of negative LNs was 6 (range, 0-30). Multivariate survival analysis yielded these prognostic variables: number of LNs examined, number of positive LNs, tumor size, extrapancreatic extension, radiotherapy (all P < .0001), and age (P = .0009). The greatest survival differences were observed for negative LN counts of 10 to 15.
CONCLUSIONS: Stage-based survival prediction of pancreatic cancer is strongly influenced by total LN counts and numbers of negative LNs obtained. Although the mechanism remains unclear and could reflect confounding factors (margin status and institutional volume), an attempt to resect and examine at least 15 LNs to yield preferably between 10 and 15 negative LNs seems sensible for curative-intent pancreatectomy.

Entities:  

Mesh:

Year:  2006        PMID: 16955385     DOI: 10.1245/s10434-006-9016-x

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  80 in total

1.  RGS16 and FosB underexpressed in pancreatic cancer with lymph node metastasis promote tumor progression.

Authors:  Ji Hyang Kim; Jin Young Lee; Kyu Taek Lee; Jong Kyoon Lee; Kwang Hyuck Lee; Kee-Taek Jang; Jin Seok Heo; Seong Ho Choi; Jong Chul Rhee
Journal:  Tumour Biol       Date:  2010-06-23

2.  Extended pancreatic resections and lymphadenectomy: An appraisal of the current evidence.

Authors:  Shailesh V Shrikhande; Savio G Barreto
Journal:  World J Gastrointest Surg       Date:  2010-02-27

Review 3.  The lymphatic system and pancreatic cancer.

Authors:  Darci M Fink; Maria M Steele; Michael A Hollingsworth
Journal:  Cancer Lett       Date:  2015-12-29       Impact factor: 8.679

4.  Pancreaticoduodenectomy: outcomes in a low-volume, specialised Hepato Pancreato Biliary unit.

Authors:  H A Kanhere; M I Trochsler; M H Kanhere; A N Lord; G J Maddern
Journal:  World J Surg       Date:  2014-06       Impact factor: 3.352

5.  Prognostic value of the lymph node ratio after resection of periampullary carcinomas.

Authors:  Shahid G Farid; Gavin A Falk; Daniel Joyce; Sricharan Chalikonda; R Matthew Walsh; Andrew M Smith; Gareth Morris-Stiff
Journal:  HPB (Oxford)       Date:  2012-11-19       Impact factor: 3.647

6.  Oncological feasibility of laparoscopic distal pancreatectomy for adenocarcinoma: a single-institution comparative study.

Authors:  S Rehman; S K P John; R Lochan; B C Jaques; D M Manas; R M Charnley; J J French; S A White
Journal:  World J Surg       Date:  2014-02       Impact factor: 3.352

7.  Clinical impact of lymphadenectomy extent in resectable esophageal cancer.

Authors:  Roderich E Schwarz; David D Smith
Journal:  J Gastrointest Surg       Date:  2007-09-02       Impact factor: 3.452

8.  N0/N1, PNL, or LNR? The effect of lymph node number on accurate survival prediction in pancreatic ductal adenocarcinoma.

Authors:  Nakul P Valsangkar; Devon M Bush; James S Michaelson; Cristina R Ferrone; Jennifer A Wargo; Keith D Lillemoe; Carlos Fernández-del Castillo; Andrew L Warshaw; Sarah P Thayer
Journal:  J Gastrointest Surg       Date:  2012-12-11       Impact factor: 3.452

9.  Redefining the R1 resection for pancreatic ductal adenocarcinoma: tumour lymph nodal burden and lymph node ratio are the only prognostic factors associated with survival.

Authors:  Biku J John; Prashant Naik; Alastair Ironside; Brian R Davidson; Guiseppe Fusai; Roopinder Gillmore; Jennifer Watkins; Sakhawat H Rahman
Journal:  HPB (Oxford)       Date:  2013-01-14       Impact factor: 3.647

10.  Accurate prediction of nodal status in preoperative patients with pancreatic ductal adenocarcinoma using next-gen nanoparticle.

Authors:  Shaunagh McDermott; Sarah P Thayer; Carlos Fernandez-Del Castillo; Mari Mino-Kenudson; Ralph Weissleder; Mukesh G Harisinghani
Journal:  Transl Oncol       Date:  2013-12-01       Impact factor: 4.243

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.